Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in
BioLine RX Ltd banner
B

BioLine RX Ltd
NASDAQ:BLRX

Watchlist Manager
BioLine RX Ltd
NASDAQ:BLRX
Watchlist
Price: 2.92 USD -4.89% Market Closed
Market Cap: $233.4m
Write Note Create Alert Ask AI

Gross Margin

50.7%
Current
Declining
by 6.2%
vs 3-y average of 56.9%

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
50.7%
=
Gross Profit
$6.5m
/
Revenue
$12.7m

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
50.7%
=
Gross Profit
$6.5m
/
Revenue
$12.7m

Peer Comparison

Country Company Market Cap Gross
Margin
IL
BioLine RX Ltd
TASE:BLRX
34.4m ILS
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
395.1B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
204.9B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
190B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
121.3B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.5B USD
Loading...
AU
CSL Ltd
ASX:CSL
87.4B AUD
Loading...
NL
argenx SE
XBRU:ARGX
41.9B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Higher than 70% of companies in Israel
Percentile
70th
Based on 676 companies
70th percentile
50.7%
Low
-11 239.1% — 17.6%
Typical Range
17.6% — 50.4%
High
50.4% — 208.2%
Distribution Statistics
Israel
Min -11 239.1%
30th Percentile 17.6%
Median 29.8%
70th Percentile 50.4%
Max 208.2%

Other Profitability Ratios

BioLine RX Ltd
Glance View

Market Cap
233.4m USD
Industry
Biotechnology

BioLineRx Ltd. is a clinical stage biopharmaceutical company, which focuses on oncology. The firm is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The firm is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.

BLRX Intrinsic Value
6.95 USD
Undervaluation 58%
Intrinsic Value
Price
B
What is Intrinsic Value?

See Also

Summary
BLRX intrinsic value, competitors valuation, and company profile.
DCF Valuation
BLRX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
BLRX stock valuation using valuation multiples.
Wall Street Estimates
BLRX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
BLRX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
What is Gross Margin?
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
How is Gross Margin calculated?

Gross Margin is calculated by dividing the Gross Profit by the Revenue.

Gross Margin
50.7%
=
Gross Profit
$6.5m
/
Revenue
$12.7m
What is BioLine RX Ltd's current Gross Margin?

The current Gross Margin for BioLine RX Ltd is 50.7%, which is below its 3-year median of 56.9%.

How has Gross Margin changed over time?

Over the last 2 years, BioLine RX Ltd’s Gross Margin has increased from 23.1% to 50.7%. During this period, it reached a low of 23.1% on Dec 31, 2023 and a high of 68.8% on Sep 30, 2024.

Back to Top
ALPHA SPREAD
Follow us
Join more than 315,700+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.